Protalix BioTherapeutics, Inc. today announced final results from the BRIGHT Phase III clinical trial evaluating pegunigalsidase alfa (PRX 102) for the potential treatment of Fabry disease. The results indicate that treatment with 2 mg/kg of PRX-102 administered by intravenous (IV) infusion every four weeks was well tolerated, and Fabry disease assessed by estimated glomerular filtration…
eTurboNews nkhani ndi za olembetsa okha. Kulembetsa ndi FREE.
Olembetsa amalowa pano Dinani apa kuti mulembetse KWAULERE
Olembetsa amalowa pano Dinani apa kuti mulembetse KWAULERE
ZOMWE MUNGACHITE PA NKHANIYI:
- today announced final results from the BRIGHT Phase III clinical trial evaluating pegunigalsidase alfa (PRX 102) for the potential treatment of Fabry disease.
- The results indicate that treatment with 2 mg/kg of PRX-102 administered by intravenous (IV) infusion every four weeks was well tolerated, and Fabry disease assessed by estimated glomerular filtration….
- Kulembetsa ndi KWAULERE.
